Search
Crizotinib
go.drugbank.com/drugs/DB08865ApprovedInvestigationalCrizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and i...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesBrentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigationalBrentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and ...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsGlycerol phenylbutyrate
go.drugbank.com/drugs/DB08909ApprovedInvestigationalGlycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP2D6 InhibitorsPomalidomide
go.drugbank.com/drugs/DB08910ApprovedInvestigationalPomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesLuliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalLuliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand nam...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP2C19 InhibitorsIndalpine
go.drugbank.com/drugs/DB08953ApprovedWithdrawnIndalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsFluocortolone
go.drugbank.com/drugs/DB08971ApprovedWithdrawnFluocortolone is a glucocorticoid with anti-inflammatory activity used topically for various skin disorders.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersCarbazochrome
go.drugbank.com/drugs/DB09012ApprovedWithdrawnCarbazochrome is a hemostatic agent that promotes clotting, preventing blood loss from open wounds. It is an oxidation product of adrenaline which enhances the microcirculatory tone . In the future this may prevent excessive blood flow d...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsSiltuximab
go.drugbank.com/drugs/DB09036ApprovedInvestigationalSiltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound I...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersCeritinib
go.drugbank.com/drugs/DB09063ApprovedInvestigationalCeritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% o...
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates